Issue 5/2014
Content (23 Articles)
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
Andrés Poveda, Xavier García del Muro, Jose Antonio López-Guerrero, Virginia Martínez, Ignacio Romero, Claudia Valverde, Ricardo Cubedo, Javier Martín-Broto
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy
Takenori Kanekawa, Hidenari Nagai, Masahiro Kanayama, Yasukiyo Sumino
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer
Yousuke Nakai, Hiroyuki Isayama, Kei Saito, Takashi Sasaki, Naminatsu Takahara, Tsuyoshi Hamada, Suguru Mizuno, Koji Miyabayashi, Keisuke Yamamoto, Dai Mohri, Hirofumi Kogure, Natsuyo Yamamoto, Kenji Hirano, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
Carlos R. Becerra, Paul Conkling, Nicholas Vogelzang, Hilary Wu, Shengyan Hong, Rajesh Narwal, Meina Liang, Fatemeh Tavakkoli, Naimish Pandya
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Jan H. Beumer, Kouros Owzar, Lionel D. Lewis, Chen Jiang, Julianne L. Holleran, Susan M. Christner, William Blum, Steven Devine, Jonathan E. Kolitz, Charles Linker, Ravi Vij, Edwin P. Alyea, Richard A. Larson, Mark J. Ratain, Merrill J. Egorin
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation
Satoshi Igawa, Masashi Kasajima, Mikiko Ishihara, Michiko Kimura, Yasuhiro Hiyoshi, Hideyuki Niwa, Seiichiro Kusuhara, Shinya Harada, Maiko Asakuma, Sakiko Otani, Ken Katono, Jiichiro Sasaki, Noriyuki Masuda
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial
Andreas Erhardt, Frank Kolligs, Matthias Dollinger, Eckart Schott, Hennig Wege, Michael Bitzer, Christiane Gog, Frank Lammert, Markus Schuchmann, Clemens Walter, Dirk Blondin, Christian Ohmann, Dieter Häussinger
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms
William D. Figg, Manish Monga, Donna Headlee, Avni Shah, Cindy H. Chau, Cody Peer, Richard Messman, Yusri A. Elsayed, Anthony J. Murgo, Giovanni Melillo, Qin C. Ryan, Mikhail Kalnitskiy, Adrian M. Senderowicz, Melinda Hollingshead, Susan G. Arbuck, Edward A. Sausville
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates
Russ Wada, Hans K. Erickson, Gail D. Lewis Phillips, Carmela A. Provenzano, Douglas D. Leipold, Elaine Mai, Holly Johnson, Jay Tibbitts
Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance
Robert G. Lingeman, Robert J. Hickey, Linda H. Malkas
Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience
Inkeun Park, Yong-Hee Kim, Dok Hyun Yoon, Sook Ryun Park, Hyeong Ryul Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin Hyug Lee, Kyung-Ja Cho, Sung-Bae Kim
Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
Jae-Lyun Lee, Se Hoon Park, Su-Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation
Kirtesh Patel, Jing Wen, Kelly Magliocca, Susan Muller, Yuan Liu, Zhuo Georgia Chen, Nabil Saba, Roberto Diaz
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Tatsushi Kodama, Masami Hasegawa, Kenji Takanashi, Yuji Sakurai, Osamu Kondoh, Hiroshi Sakamoto
Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
Philip M. Tedeschi, Yamini K. Kathari, Iqra N. Farooqi, Joseph R. Bertino
Prognostic value of human papillomavirus in anal squamous cell carcinoma
Paola Simona Ravenda, Elena Magni, Edoardo Botteri, Michela Manzotti, Massimo Barberis, Davide Vacirca, Cristina Maria Trovato, Veronica Dell’Acqua, Maria Cristina Leonardi, Mario Sideri, Nicola Fazio, Maria Giulia Zampino
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J. Mateo, J. Berlin, J. S. de Bono, R. B. Cohen, V. Keedy, G. Mugundu, Lianglin Zhang, A. Abbattista, C. Davis, C. Gallo Stampino, H. Borghaei
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
Ami V. Desai, Elizabeth Fox, L. Mary Smith, Allison Pecha Lim, John M. Maris, Frank M. Balis
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
Claire Fabre, Marco Gobbi, Cyrine Ezzili, Mustapha Zoubir, Marie-Paule Sablin, Karen Small, Ellie Im, Nabeegha Shinwari, Da Zhang, Honghong Zhou, Christophe Le Tourneau
Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients
Sonam Tulsyan, Gaurav Agarwal, Punita Lal, Balraj Mittal
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
Marije Slingerland, Dagmar Hess, Sally Clive, Sunil Sharma, Per Sandstrom, Niklas Loman, Maria G. Porro, Song Mu, Edward Waldron, Sue-zette Valera, Hans Gelderblom
Predicting success in regulatory approval from Phase I results
Laeeq Malik, Alex Mejia, Helen Parsons, Benjamin Ehler, Devalingam Mahalingam, Andrew Brenner, John Sarantopoulos, Steven Weitman